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Abstract: Background: Recent studies indicate that enhanced neuronal stress responses are associated
with adverse cardiovascular outcomes. A chronic inflammatory state seems to mediate this detrimental
neuro-cardiac communication. Statins are among the most widely prescribed medications in primary and
secondary cardiovascular disease (CVD) prevention and not only lower lipid levels but also exhibit strong
anti-inflammatory and neuroprotective effects. We therefore sought to investigate the influence of statins
on neuronal stress responses in a patient cohort at risk for CVD. Methods: 563 patients (61.5 ± 14.0 years)
who underwent echocardiography and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography
(PET) were retrospectively identified. Metabolic activity of the amygdala, a part of the brain’s salience
network, was quantified by 18F-FDG uptake, while normal cardiac morphology and function were assured
by echocardiography. Vertebral bone marrow metabolism, a marker of inflammatory activity, was mea-
sured by 18F-FDG PET. Results: Increased neuronal stress responses were associated with an increased
inflammatory activity in the bone marrow (r = 0.152, p = 0.015) as well as with a subclinical reduction
in left ventricular ejection fraction (LVEF, r = -0.138, p = 0.025). In a fully-adjusted linear regression
model, statin treatment was identified as an independent, negative predictor of amygdalar metabolic
activity (B-coefficient -0.171, p = 0.043). Conclusions: Our hypothesis-generating investigation suggests
a potential link between the anti-inflammatory actions of statins and reduced neuronal stress responses
which could lead to improved cardiovascular outcomes. The latter warrants further studies in a larger
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Abstract: Background: Recent studies indicate that enhanced neuronal stress responses are associated
with adverse cardiovascular outcomes. A chronic inflammatory state seems to mediate this detri-
mental neuro-cardiac communication. Statins are among the most widely prescribed medications in
primary and secondary cardiovascular disease (CVD) prevention and not only lower lipid levels but
also exhibit strong anti-inflammatory and neuroprotective effects. We therefore sought to investigate
the influence of statins on neuronal stress responses in a patient cohort at risk for CVD. Methods:
563 patients (61.5 ± 14.0 years) who underwent echocardiography and 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography (PET) were retrospectively identified. Metabolic activity
of the amygdala, a part of the brain’s salience network, was quantified by 18F-FDG uptake, while
normal cardiac morphology and function were assured by echocardiography. Vertebral bone marrow
metabolism, a marker of inflammatory activity, was measured by 18F-FDG PET. Results: Increased
neuronal stress responses were associated with an increased inflammatory activity in the bone mar-
row (r = 0.152, p = 0.015) as well as with a subclinical reduction in left ventricular ejection fraction
(LVEF, r = −0.138, p = 0.025). In a fully-adjusted linear regression model, statin treatment was iden-
tified as an independent, negative predictor of amygdalar metabolic activity (B-coefficient −0.171,
p = 0.043). Conclusions: Our hypothesis-generating investigation suggests a potential link between
the anti-inflammatory actions of statins and reduced neuronal stress responses which could lead to
improved cardiovascular outcomes. The latter warrants further studies in a larger and prospective
population.
Keywords: amygdala; statins; inflammation; dyslipidaemia; PET
1. Introduction
Inflammation plays a fundamental role in the evolution and progression of cardio-
vascular disease [1,2]. Beyond their lipid-lowering properties, statins exert strong anti-
inflammatory effects through inhibition of the mevalonate pathway [3]. Moreover, statins
exhibit neuroprotective features by reducing neuroinflammatory responses such as sup-
pression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and
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decrease of pro-inflammatory cytokines. They further promote neurogenesis by modula-
tion of Ras homolog family member A (RhoA), protein kinase B (Akt), and wingless-related
integration site (Wnt) signalling pathways [4].
Complex neural functions such as cognition and emotion are influenced by a group
of interconnected neural structures called the brain’s salience network. Particularly in
emotional stress generation, this network is known to play an important role [5]. Activa-
tion of the brain’s salience network, which includes the amygdala as a key component [6],
results in autonomic, hormonal, and behavioral changes, ulimately leading to anxiety
and stress [7]. The efferent projections of the amygdala to the brainstem are involved in
sympathetic responses to psychological stress [8]. Both an upregulation of bone marrow
activity and inflammation of the arteries was proposed as a potential mechanism intercon-
necting increased amygdalar metabolism with an elevated risk of adverse cardiovascular
events [7,9]. Since heightened resting activity of the amygdalais an independent predictor
of cardiovascular outcome [7], we sought to investigate the effect of statin therapy on
amygdalar metabolism and inflammation in an aged study cohort at risk for cardiovascular
disease (CVD).
2. Material and Methods
A total of 563 patients (aged 61.5 ± 14.0 years, 36.2% women) underwent both stan-
dardized echocardiography and full-body 18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET) / computed tomography (CT) to assess cardiac function and resting
amygdalar glucose metabolism (mean time interval [±standard error, SE] 43.4 ± 2.0
days) [10]. After exclusion of 296 patients due to either the presence of chronic inflamma-
tory disorders or active malignancies, impaired left ventricular ejection fraction (LVEF)
<50% (n = 93), presence of wall motion abnormalities (n = 149), and/or known coronary
artery disease (n = 129), and diabetes (n = 106), a cohort of 267 patients free of clinical
CVD (aged 58.3 ± 14.8 years, 47.9% women) were retrospectively analyzed (Figure 1).
Serial regions of interest (ROI) to measure 18F-FDG standardized uptake value (SUV) were
placed around both amygdalae using the brain maximum probability map (“Hammer-
smith atlas” [11]), as previously described [12]. Normalization was then performed against
cerebellar activity, which was determined by serial placement of ROI encompassing both
the left and the right cerebellum. 18F-FDG bone marrow was retrieved by serial placement
of standardized ROI (10 mm diameter) in the center from the first thoracic to the fifth
lumbar vertebral body. Image analysis was performed by using PMOD software V4.1
(PMOD Technologies LLC, Zurich, Switzerland). Statistical analysis was performed using
IBM SPSS, version 25.0 (IBM Corp, Armonk, NY, USA). Pearson product-moment test
was applied to identify associations, and after confirming normal distribution of data
and excluding collinearity issues, stepwise linear regression models were used to identify
predictor variables for amygdalar 18F-FDG uptake (smallest probability of F ≤ 0.05, largest
probability of F ≥ 0.1). As this is an explorative investigation, no pre-specified level of
significance was applied. Thus, the level of evidence was quantified continuously as
recommended [13].
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Figure 1: Study cohort. Study flow-chart visualizing initial cohort and excluded patients on 




Figure 1. Clinical study cohort. Study flow chart visualizing initial complete study cohort and excluded patients on
pre-defined criteria (left ventricular ejection fraction, motion abnormalities, known coronary artery disease, and diabetes
mellitus). Totally 267 patients free of clinical cardiac disease entered the final study population for statistical investigation.
3. Results
No significant differences in baseline characteristics were observed between patients
with and without statin therapy, except for age (p < 0.001) and dyslipidaemia (p = 0.003,
Table 1). The average statin dose taken was 28.8 ± 18.0 mg in our cohort.
Table 1. Patient baseline characteristics.
Patient Baseline Characteristics Total (n = 267) Statin (n = 42) No Statin (n = 225)
p-Value (Statin vs.
No Statin)
Age (years), mean ± SD 58.3 ± 14.8 66.1 ± 10.2 56.9 ± 15.1 <0.001
Hypertension, n(%) 82(30.7) 16(6.0) 66(24.7) 0.227
Dyslipidemia, n(%) 18(6.7) 8(3.0) 10(3.7) 0.003
Obesity, n(%) 39(14.6) 6(2.2) 33(12.4) 1.000
Family history of CAD, n(%) 3(1.1) 1(0.4) 2(0.7) 0.403
Smoking, n(%) 41(15.4) 7(2.6) 34(12.7) 0.816
Alcohol, n(%) 18(6.7) 1(0.4) 17(6.4) 0.323
LVEF (%), mean ±SD 61.8 ± 5.8 61.6 ± 5.5 61.8 ± 5.9 0.829
Blood glucose (mmol/L), mean ± SD 5.6 ± 1.3 5.4 ± 0.9 5.7 ± 1.4 0.272
Creatinine (µmol/L), mean ± SD 102.3 ± 90.4 118.1 ± 123.7 99.6 ± 83.6 0.387
CRP (mg/L), mean ± SD 53.1 ± 68.9 63.2 ± 82.1 51.1 ± 66.4 0.454
NT-proBNP (ng/L), mean ± SD 1553 ± 2468 2062 ± 3383 1468 ± 2367 0.664
Neutrophiles (×103/µL), mean ± SD 5.85 ± 3.51 6.62 ± 3.41 5.72 ± 3.53 0.300
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Table 1. Cont.
Patient Baseline Characteristics Total (n = 267) Statin (n = 42) No Statin (n = 225)
p-Value (Statin vs.
No Statin)
Lymphocytes (×103/µL), mean ± SD 1.34 ± 0.74 1.32 ± 0.66 1.34 ± 0.75 0.900
18F-FDG bone marrow (SUV),
mean ± SD
1.91 ± 0.50 1.85 ± 0.43 1.92 ± 0.51 0.424
18F-FDG amygdala (SUV), mean ± SD 0.81 ± 0.10 0.80 ± 0.10 0.81 ± 0.10 0.722
CAD, coronary artery disease; CRP, C-reactive protein; 18F-FDG, 18F-fluorodeoxyglucose; LVEF, left ventricular ejection fraction; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; SD, standard deviation; SUV, standardized uptake value. Data are displayed as mean ± SD or
frequencies (in percentage). Two-sided p-values are depicted. Percentage values refer to the total patient number of 267.
As previously demonstrated [14], an enhanced bone marrow 18F-FDG uptake was
associated with increased plasma C-reactive protein (CRP) levels (r = 0.384, p < 0.001)
supporting the notion that augmented bone marrow metabolic activity indicates an inflam-
matory state. Further, a positive association of resting amygdalar activity with vertebral
bone marrow 18F-FDG uptake (r = 0.152, p = 0.015, Figure 2A) and a negative correlation
between amygdalar uptake and LVEF (r = −0.138, p = 0.025, Figure 2B) were detected.
In contrast to patients without statin therapy, these correlations were no longer evident in
patients on statin therapy (n = 42, p = not significant).
−
Figure 2. Association of resting amygdala activity with bone marrow metabolism and cardiac
function. Pearson product-moment correlation of 18F-FDG amygdala uptake (standardized uptake
value ratio, SUVR) shows a positive correlation with bone marrow activity (standardized uptake
value, SUV, (A)) and a negative association with left ventricular ejection fraction (LVEF, %, (B)).
Correlation coefficients and p-values are indicated. 18F-FDG, 18F-fluorodeoxyglucose.
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In a first stepwise linear regression model adjusted for CVD risk factors including
dyslipidaemia (n = 18), hypertension (n = 82), obesity (n = 39), positive family history for
cardiovascular disease (n = 3), and smoking (n = 41), both enhanced 18F-FDG bone marrow
uptake and reduced LVEF were selected as predictors of an increased amygdalar activity
(B-coefficient for bone marrow uptake: 0.150, p = 0.016; for LVEF: −0.127, p = 0.041). In a
second stepwise linear regression model that included the predictor variables age, CVD
risk factors, medications (angiotensin converting enzyme inhibitors [n = 38], angiotensin II
receptor blockers [n = 38], beta blockers [n = 65], loop diuretics [n = 41], aspirin [n = 52],
and statins [n = 42]), as well as kidney function, statins remained in the model as the only
independent predictor of amygdalar activity (B-coefficient: −0.171, p = 0.043).
In a three-way ANOVA analysis with 18F-FDG amygdalar metabolism as dependent
and statins, dyslipidaemia, and sex as independent variables, both statin (p = 0.024) and
sex (p = 0.038) led to significantly different metabolic activity of the amygdala, whereas
dyslipidaemia alone (p = 0.584) and the combination of all three variables (p = 0.193) had no
influence on amygdalar metabolism. However, the presence of statins in combination with
dyslipidaemia was associated with the most distinct difference in amygdalar metabolism
resulting in a lower mean amygdalar activity as compared to the absence of statins and
dyslipidaemia (0.76 ± 0.12 vs. 0.81 ± 0.10, p = 0.015, Figure 3).
−
Figure 3. Impact of statins on amygdalar activation pattern. In a three-way ANOVA, an interaction term consisting of
statins and dyslipidaemia was associated with a blunted amygdalar activity (p = 0.015). Interaction terms consisting of sex,
statins and/or dyslipidaemia were statistically not evident (p > 0.05). The first left two bars show resting amygdalar activity
of patients without statins and the right two bars depict patients with statins therapy. Further, white bars correspond to
those patients without and grey bars to those patients with dyslipidemia. For reasons of improved readability, the variable
“sex” was not included in this Figure. Error bars display standard error, SE. p-value is depicted.
4. Discussion
We demonstrate that statin therapy is associated with reduced amygdalar activity in
aged patients at risk for CVD. We further confirm previous findings [7] by reporting an
association of amygdalar activity with inflammatory processes via an enhanced production
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of inflammatory progenitor cells in the bone marrow and the relation of vertebral bone
marrow metabolism with plasma CRP levels. Moreover, the association between an ele-
vated metabolic activity of the amygdala and a subclinical reduction in LVEF in our study
suggests a detrimental link between an enhanced neuronal stress response and impaired
cardiac function. The latter is in line with the observation that persistent activation of
β-adrenergic receptors leads to an upregulation of cytokines, macrophage infiltration, and
subsequent cardiac fibrosis by inflammasome-dependent activation of interleukin-18 in
myocardial cells [15]. Notably, statins inhibit the 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase, the rate-limiting enzyme in the mevalonate pathway. Downstream
metabolites of this pathway are essential for the attachment of guanosine triphosphatases
(i.e., rat sarcoma [Ras], Rac, and ras homolog family member A [RhoA]) to the cell mem-
brane and play critical roles in various steps of immune cell activation, metabolism, and
survival [16]. Among individuals who received statin therapy, resting amygdalar activity
was no longer associated with 18F-FDG bone marrow uptake. Conversely, among those
who did not receive statin therapy, the association of enhanced resting amygdalar activ-
ity with higher 18F-FDG bone marrow uptake and reduced LVEF was retained. These
observations suggest that the deleterious effects of the neuro-hematopoetic axis on the
cardiovascular system might be modifiable by optimum medical therapy. Proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), an enzyme involved in low-density lipoprotein
receptor degradation has been shown to not only promote early atherosclerosis but also
being ubiquitously present in the body including neural tissue [17].
Given that selective inhibition of PCSK9 by monoclonal anti-bodies effectively reduced
levels of cholesterol and adverse cardiovascular events, the involvement of PCSK9 in
lipid metabolism in conjunction with the downregulating effects of statins on amygdalar
metabolism merits further investigation.
Several limitations of our study need to be pointed out: First, this is a single-center and
retrospective cohort study with a purely observational design and thus carries a limited
generalizability of its results as well as a potential for referral bias. Second, patients did
not receive magnetic resonance imaging of neural structures. Thus, limitations apply for
regional mapping of the amygdala. Further, partial volume correction was not conducted.
Third, age-based neurodegeneration and brain atrophy may act as confounders in this
study. Fourth, although patients with impaired LVEF or clinical cardiovascular disease
were excluded from our study, a slightly elevated overall N-terminal pro-B-type natriuretic
peptide (NT-proBNP) level was observed in our cohort. Increased NT-proBNP concentra-
tions are present in many non-cardiac conditions such as pulmonary or renal disease and
are commonly seen in older patients. Therefore, given the increased age and the higher
prevalence of comorbidities and CVD risk factors in our study cohort, the possibility that
unmeasured variables have influenced our findings cannot be completely ruled out. Fifth,
the exact duration of statin therapy was not reliably retrievable from our data sets. Thus, no
conclusions can be made concerning the duration of statin therapy and its effect dynamics
on amygdalar activity. Therefore, the findings of our investigation should be regarded
as hypothesis-generating and will have to be further investigated in a larger and ideally
prospective cohort trial.
5. Conclusions
Given the anti-inflammatory properties of statins, our observation of a reduced neu-
ronal stress response in patients on statin therapy suggests a novel mechanistic link on
how statins could exert cholesterol-independent, “pleiotropic” effects on cardiovascular
health. The modulation of neuronal stress responses by statins and the potential cardio-
protective effect of this association provides new insights into the highly investigated
neuro-haematopoietic-vascular axis and might help to explore new concepts of primary
and secondary CVD prevention.
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